Abstract: The present invention has for its object to provide a medicinal composition comprising coenzyme Q10 as an active ingredient, which composition features an enhanced absorption after oral administration. The present invention is directed to a medicinal composition comprising coenzyme Q10 as an active ingredient with the reduced form of coenzyme Q10 accounting for more than 20 weight % of said coenzyme Q10.

Abstract: The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs.

Abstract: A method for treatment of diseases caused by Chlamydia infection is disclosed comprising administering a rifamycin of the formula (I): ##STR1## wherein R.sup.1 is hydrogen atom or acetyl, and X is oxygen, sulfur or a group NR, in which R is hydrogen, an alkyl group having 1 to 7 carbon atoms or a group of the formula (II): ##STR2## in which n is an integer of 1 to 3; or a physiologically acceptable salt thereof.

Abstract: The present invention provides an ophthalmic composition comprising a sleep inducing substance or a sleep inhibiting substance, and the sleep inducing substance or the sleep inhibiting substance is derived from an organism. Thus, the invention provides an ophthalmic composition comprising a sleep adjusting substance which normalizes irregularity of the rhythm of sleep and a liquid ophthalmic medicament comprising the composition, the composition and the medicament being safe and obtainable by anyone, and a method for regulating the rhythm of sleep comprising instilling the ophthalmic medicament including the sleep adjusting substance to an individual.

Abstract: The present invention is directed to a sticky composition for medical use comprising a tackifier resin and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein silicon atom thereof is bound with a hydroxyl group or hydrolytic group, and to a transdermal drug delivery preparation incorporating said sticky composition as a drug carrier. The sticky composition of the present invention possesses excellent adhesive properties, very low skin irritancy and good compatibility with the site of plastering and thus perform as a very safe and effective medical adhesive. The transdermal drug delivery preparation of the present invention offers excellent drug release from the sticky composition.

Abstract: The present invention relates to a method for producing a microgranulated particle having particle size of not more than 0.2 mm, wherein a fine powder with the average particle size of not more than 10 .mu.m, which is being agitated, tumbled or fluidized, is granulated, with a solution containing a binder alone or a binder and a surfactant being sprayed onto the surface thereof. The present invention allows to produce pharmaceutical preparations for poorly soluble and poorly absorbable drugs and preparations requiring a high content of the active ingredient. Also, it can provide an easy-to-handle powdery microgranulated particle in the field of food and fertilizers.

Abstract: A cognition enhancer comprising, as an effective ingredient, a bicyclic compound containing nitrogen atom having the general formula (I): ##STR1## or a physiologically acceptable salt thereof.

Abstract: The present invention is directed to a stable pharmaceutical composition wherein the absorbability of a lipophilic drug which is insoluble or practically insoluble in water or another drug such as a bioactive peptide in oral administration has been improved to such extent that a high level of blood concentration can be retained, and to a method for producing such a stable pharmaceutical composition. The pharmaceutical composition of the present invention offers improvements in the absorbability, for example, a high level of blood concentration can be retained for a long time in oral administration because it is highly resistant to lipase. Also, the pharmaceutical composition is highly safe because the emulsifier used is derived from mammalian milk.

Abstract: There are described a phenoxybenzene derivative having the formula (I): ##STR1## wherein R.sup.1 is hydrogen atom; an alkyl group having 1 to 3 carbon atoms; --OR.sup.6 or a halogen atom,R.sup.2 is hydrogen atom, nitro group or amino group,R.sup.3 is hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 5 carbon atoms, allyl group, vinyl group or --(CH.sub.2)n.sup.1 R.sup.7R.sup.4 is hydrogen atom, an alkyl group having 1 to 3 carbon atoms or --(CH.sub.2)n.sup.3 R.sup.25R.sup.5 hydrogen atom; an alkyl group having 1 to 3 carbon atoms; or phenyl group,X is ##STR2## wherein Y is oxygen atom or sulfur atom; or --CHR.sup.27 -- and line means a single bond or a double bond provided that n is 2 in case that the line means a single bond and n is 1 in case that the line means a double bond, ora pharmacologically acceptable salt thereof,a cognition enhancer comprising the same as an effective ingredient andan antidepressant comprising the same as an effective ingredient.

Abstract: A cholesterol or body weight regulating material comprising an enzyme resistant starch is disclosed. A composition which contains said enzyme resistant starch is also disclosed. A food, food material, and beverage, containing said enzyme resistant starch are further disclosed. A method for regulating cholesterol or body weight is still further disclosed. Those are effective not only for lowering cholesterol level, but for preventing obesity.

Abstract: A hydroxystyrene derivative represented by the formula (I): ##STR1## wherein when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O- (R.sup.5 : H, a C.sub.1 to C.sub.5 alkyl group or benzyl group) and R.sup.2 : benzyl group or PhSCH.sub.2, R.sup.3 and R.sup.4 are taken together to represent --CONH--CS--S--, ##STR2## (X.sup.1 : H, a halogen, methyl group, ethyl group, R.sup.7 O-- (R.sup.7 : methyl or ethyl group), nitro group, aminosulfonyl group or amino group, m.sup.1 : 1 or 2), pyridyl group, furyl group or thienyl group, n.sup.1 : an integer of 0 to 3); when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : as defined above) and R.sup.2 : benzyl group, R.sup.3 : cyano group and R.sup.4 : a carbamoyl group, or R.sup.3 and R.sup.4 are taken together to represent --CO--Y--CH.sub.2 CH.sub.2 -- (Y: O or --NH--) or ##STR3## and when R.sup.1 and R.sup.2 : a C.sub.1 to C.sub.3 alkyl group, R.sup.3 and R.sup.

Abstract: A hydroxystyrene derivative represented by the formula (I): ##STR1## wherein when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : H, a C.sub.1 to C.sub.5 alkyl group or benzyl group) and R.sup.2 : benzyl group or PhSCH.sub.2, R.sup.3 and R.sup.4 are taken together to represent --CONH--CS--S--, ##STR2## (X.sup.1 : H, a halogen, methyl group, ethyl group, R.sup.7 O-- (R.sup.7 : methyl or ethyl group), nitro group, aminosulfonyl group or amino group, m.sup.1 : 1 or 2), pyridyl group, furyl group or thienyl group, n.sup.1 : an integer of 0 to 3); when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : as defined above) and R.sup.2 : benzyl group, R.sup.3 : cyano group and R.sup.4 : a carbamoyl group, or R.sup.3 and R.sup.4 are taken together to represent --CO--Y--CH.sub.2 CH.sub.2 -- (Y: O or --NH--) or ##STR3## and when R.sup.1 and R.sup.2 : a C.sub.1 to C.sub.3 alkyl group, R.sup.3 and R.sup.

Abstract: A hydroxystyrene derivative represented by the formula (I): ##STR1## Wherein when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O--(R.sup.5 : H, a C.sub.1 to C.sub.5 alkyl group or benzyl group) and R.sup.2 : benzyl group or PhSCH.sub.2, R.sup.3 and R.sup.4 are taken together to represent --CONH--CS--S--, ##STR2## (X.sub.1 : H, a halogen, methyl group, ethyl group, R.sup.7 O--(R.sup.7 : methyl or ethyl group), nitro group, aminosulfonyl group or amino group, m.sup.1 : 1 or 2), pyridyl group, furyl group or thienyl group, n.sup.1 : an integer of 0 to 3); when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O--(R.sup.5 : as defined above) and R.sup.2 : benzyl group, R.sup.3 : cyano group and R.sup.4 : a carbamoyl group, or R.sup.3 and R.sup.4 are taken together to represent --CO--Y--CH.sub.2 CH.sub.2 --(Y: O or --NH--) or ##STR3## and when R.sup.1 and R.sup.2 : a C.sub.1 to C.sub.3 alkyl group, R.sup.3 and R.sup.

Abstract: A hydroxystyrene derivative represented by the formula (I): ##STR1## wherein when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : H, a C.sub.1 to C.sub.5 alkyl group or benzyl group) and R.sup.2 : benzyl group or PhSCH.sub.2, R.sup.3 and R.sup.4 are taken together to represent --CONH--CS--S--, ##STR2## (X.sup.1 : H, a halogen, methyl group, ethyl group, R.sup.7 O-- (R.sup.7 : methyl or ethyl group), nitro group, aminosulfonyl group or amino group, m.sup.1 : 1 or 2), pyridyl group, furyl group or thienyl group, n.sup.1 : an integer of 0 to 3); when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : as defined above) and R.sup.2 : benzyl group, R.sup.3 : cyano group and R.sup.4 : a carbamoyl group, or R.sup.3 and R.sup.4 are taken together to represent --CO--Y--CH.sub.2 CH.sub.2 -- (Y: O or --NH--) or ##STR3## and when R.sup.1 and R.sup.2 : a C.sub.1 to C.sub.3 alkyl group, R.sup.3 and R.sup.

Abstract: A 3-phenylthiomethylstyrene derivative having the general formula (1): ##STR1## or salt thereof with a base, when X is hydroxyl group, R.sup.1 is hydrogen atom or R.sup.2 is hydrogen atom, a process for preparing the 3-phenylthiomethylstyrene derivative (1), and an antiallergic agent and a tyrosinekinase inhibiting agent containing the 3-phenylthiomethylstyrene derivative (1) as an effective component. The compound (1) of the present invention is a useful intermediate for preparing various organic compounds, and has excellent antiallergic and tyrosinekinase inhibiting activities.

Abstract: A new anti-inflammatory, analgesic, and antipyretic pharmaceutical composition is disclosed which contains a 3,5-di-tert-butyl-4-hydroxystyrene derivative of the formula: ##STR1## wherein R.sup.1 stands for a group represented by COR.sup.3 [R.sup.3 denotes a group of OR.sup.4 (R.sup.4 is a hydrogen atom or an alkyl group with C.sub.1 .about.C.sub.4), an alkyl group with C.sub.1 .about.C.sub.3, a phenyl group, or an amino group], a nitro group, or an alkylsulfonyl group represented by SO.sub.2 R.sup.5 (R.sup.5 is an alkyl group with C.sub.1 .about.C.sub.3); and R.sup.2 stands for a hydrogen atom, an alkyl group with C.sub.1 .about.C.sub.4, a hydroxyalkyl group with C.sub.1 .about.C.sub.4, a cyano group, or an acyl group represented by COR.sup.6 (R.sup.6 is an alkyl group with C.sub.1 .about.C.sub.3),or its pharmaceutically acceptable salt as an active ingredient in association with pharmaceutical excipients.

Abstract: Novel compounds, 3,5-di-tert-butylstyrene derivatives and their salts, are disclosed, which derivatives are represented by the general formula: ##STR1## wherein R.sup.1 stands for an acyloxy group represented by R.sup.3 COO (R.sup.3 is a hydrogen atom or an alkyl group with C.sub.1 -C.sub.6), an alkoxyl group of R.sub.4 O (R.sup.4 is an alkyl group with C.sub.1 -C.sub.4), a hydroxyl group, or a hydrogen atom; R.sup.2 stands for ##STR2## (R.sup.5 is a hydrogen atom or an alkyl group with C.sub.1 -C.sub.3 and X.sup.1 is CH.sub.2 or an oxygen atom), ##STR3## (R.sup.5 and X.sup.1 are each the same as defined above), or ##STR4## (X.sup.2 is an oxygen or sulfur atom).

Abstract: A new antibiotic designated as auromomycin is prepared from the culture broth of Streptomyces macromomyceticus, a macromomycin-producing strain, as yellow crystals. Auromomycin is recovered in pure form from the culture broth by using hydrophobic chromatography with Octyl Sephalose CL-4B or Phenyl Sepharose CL-4B.